Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

EML4-ALK fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. Precise detection of ALK fusions may yield critical information for selection of appropriate therapy and hence improve patient survival...

Full description

Bibliographic Details
Main Authors: Yingying Zhu, Ran Jia, Yang W. Shao, Liuqing Zhu, Qiuxiang Ou, Man Yu, Xue Wu, Yanbei Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Oncology
Subjects:
lung adenocarcinoma
ALK rearrangement
alectinib
liquid biopsy
brain metastases
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01259/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01259/full

Similar Items